GSK Reports P-II (PERLA) Trial Results of Jemperli (dostarlimab) for Metastatic Non-Squamous Non-Small Cell Lung Cancer
Shots:
- The P-II (PERLA) trial evaluating dostarlimab + CT vs pembrolizumab + CT in 243 patients with metastatic non-sq. NSCLC
- The trial met its 1EPs of ORR as determined by BICRs & 2EPs of PFS with PD-L1 expression subgroups. The safety & tolerability profile was consistent with prior clinical trials of similar regimens & the results will be presented at an upcoming scientific meeting.
- Jemperli is being studied in registrational enabling studies as monothx. and in combination regimens incl. recurrent or primary advanced EC, stage III or IV NMEOC & other advanced solid tumors or metastatic cancers. The therapy is being evaluated in the P-III (COSTAR Lung) trial in combination therapy for advanced NSCLC
Ref: GSK | Image: GSK
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
